icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm
12 Mar, 2021 11:50

US hoarding millions of doses of unapproved AstraZeneca vaccine as EU & others suffer shortages – reports

US hoarding millions of doses of unapproved AstraZeneca vaccine as EU & others suffer shortages – reports

Washington has reportedly refused a request by AstraZeneca to loan some of the US’ stockpile of its Covid-19 vaccine – which cannot be used there yet – and deliver it to the EU, where the supplier is failing to meet its targets.

The rejection, reported by the New York Times based on information from unnamed sources in the Biden administration, showcases how rivalry over medical supplies may go against longstanding alliances – even ones as celebrated as the trans-Atlantic partnership.

The EU is facing a shortage of vaccines against Covid-19 and has been threatening to impose export controls in response. A shipment of 250,000 doses from Italy to Australia has already been banned by Rome.

Also on rt.com EU's von der Leyen threatens further Covid vaccine export controls, says AstraZeneca supplied less than 10% of agreed jabs

The US already has tens of millions of doses of AstraZeneca’s vaccine stored on its soil, but they will not be deployed for weeks. The Federal Drug Administration (FDA) is yet to receive a request for approval for emergency use of the product, pending results of a clinical trial currently being conducted by the British-Swedish company. Regulators in some 70 countries have approved it, however, and could use extra supplies, should the US release its reserves.

According to the NYT, there are about 30 million doses of the vaccine stored at AstraZeneca’s facility in West Chester, Ohio. Tens of millions more will be available once a Maryland company called Emergent BioSolutions fills vials with the produced drug and packages them. In total, the US has ordered 300 million doses of the AstraZeneca shot.

Also on rt.com EU to seek AstraZeneca doses from US amid Covid-19 vaccine supply shortfalls – media

The US’ ultimate need for the product remains in question, though, since FDA approval is not expected for weeks – and alternatives from Moderna, Pfizer, and Johnson & Johnson are being produced in the country in increasing numbers.

The US manufacturing roadmap seeks a target of more than a billion doses by the end of the year, most of it ready by summer. That number is more than enough to vaccinate the entire population.

Washington “may only briefly, or never, need the AstraZeneca doses if they are cleared for emergency use,” the Times wrote. The stockpile also comes with an expiration date – the vaccine can be stored for up to six months, according to producer’s recommendations.

Biden pledged this week to offer any surplus of vaccines against Covid-19 to other nations, but only after the needs of Americans are met. The US partially funded the development of the AstraZeneca vaccine and produced it under the Defense Production Act, which means the president will have to approve shipments to other nations. Such a move would come at a political cost to Biden, should he take it with the US population still not fully immunized.

Also on rt.com The AstraZeneca Covid-19 jab is ‘extraordinarily favorable’, French vaccine tsar says, dismissing fatal side effect link

The news comes as AstraZeneca and EU officials scramble to convince people that the vaccine is safe to take in the wake of a report that it may cause potentially fatal blood clots. Several member states have suspended its rollout, pending more information about the possible side effect, which is being investigated by the European Medicines Agency (EMA), the EU’s drug regulator.

Think your friends would be interested? Share this story!